Table 1.

Summary of principal reported trials.

	Trial	Enrolled Patients	ORR	PFS	CRS	ICANS-Like
Blinatumomab	Phase 1 [42]	r/r NHL (N = 38); aNHL (N = 5)	64% (CR 36%)	Median PFS 1.5 years (median follow-up 4.6 years)	20% > G3	22% G 3
	Phase 2 [43]	r/r aNHL (N = 25)	43% (CR19%)	Median PFS 3.7 years (median follow-up 15 months)	13% > G3	22% G 3
Glofitamab	Phase 1 [44]	r/r NHL (N = 52); aNHL (N = 10)	67% (CR 54%) iNHL/61% (CR 54%) aNHL	NR	4% > G3	NR
Mosunetuzumab	Phase 1/2b [45]	r/r NHL (N = 270); aNHL (N = 116)	63% (CR 43%) iNHL/37% (CR 19%) aNHL	NR	1% G3; no G4	1.1% G3
Odronetoxomab	Phase 1 [46]	r/r NHL (N = 136); aNHL (N = 78)	55% (CR 55%)/33% (CR 21%) in CAR T r/r	NR	7% > G3	4% G3
Epcoritamab	Phase 1 [47]	r/r NHL (N = 68); aNHL (N = 46)	80% (CR 60%) iNHL/91% (CR 55%) aNHL (for maximum dose)	NR	no G3	3% G3